Trial Profile
A Phase I/II Clinical Trial of Lenalidomide in Combination With Oral Cyclophosphamide in Patients With Previously Treated Hormone Refractory Prostate Cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Lenalidomide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 07 May 2018 Status changed from active, no longer recruiting to discontinued.
- 29 Mar 2010 New trial record